IN8BIO INC

NASDAQ: INAB (IN8bio, Inc.)

Last update: 20 hours ago

0.790

-0.03 (-3.66%)

Previous Close 0.820
Volume 11,693
Price / Book 0.570
52 Weeks Range
0.724 (-8%) — 2.73 (245%)
Diluted EPS (TTM) -13.20
Total Debt/Equity (MRQ) 30.79%
Current Ratio (MRQ) 4.30
Operating Cash Flow (TTM) -19.35 M
Levered Free Cash Flow (TTM) -8.68 M
Return on Assets (TTM) -73.25%
Return on Equity (TTM) -174.66%

AIStockmoo Score

-2.5
Earns below its cost of capital. Returns on capital rising. info
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Downtrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Institutions net -1.84% of shares in their latest 13F filings: 5 holders increased, 9 decreased (quarter to 30 Sep 2026). info
Short interest -82.7% from 31 Aug to 30 Oct 2026, 1 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Levels trending down. info
Final Score -2.52
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock IN8bio, Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
INAB - - - 0.570 -2.5
HLVX 103 M - - 0.710 0.0
MEIP 49 M - - - 0.0
SONN 33 M - - 2.07 -1.4
ANIX - - - 6.26 -1.6
PLRX - - - 0.320 -3.8

Select this tab to load the latest available analysis.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 4.20%
% Held by Institutions 20.95%

Ownership

Name Date Shares Held
Texas Capital Bank Wealth Management Services Inc 30 Sep 2026 23,521

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 34.95%

Positions Holders Shares
Increased 5 72,270
Decreased 9 189,613
New 2 10,936
Sold out 2 96,337

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 15,733 1.0
15 Oct 2026 32,797 1.0
30 Sep 2026 46,440 1.0
15 Sep 2026 63,110 2.2
31 Aug 2026 90,842 1.6
14 Aug 2026 139,903 1.4

FINRA short interest via Nasdaq, reported twice a month.

1 Positive 0 Negative 2 Neutral
Date Type Details
16 Nov 2026 Yahoo Finance IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC) 50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group Median progression-free survival (mPFS) of 13.0…
06 Nov 2026 Yahoo Finance IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the…
05 Nov 2026 Yahoo Finance IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & DevelopmentReceived third-party recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers for autoimmune diseaseRemain…
22 Sep 2026 Yahoo Finance IN8bio to Present at Sidoti Small-Cap Virtual Conference
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and…
10 Sep 2026 Yahoo Finance IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and…
09 Sep 2026 Yahoo Finance IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance…

Technical Setup Medium

Trend order
Slope
Entry
Volume
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days.
Nearest support: 0.777 – 0.823 · moderate level
Nearest resistance: 0.847 – 0.983 · strong level · tested often, may give way

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria